Article

Autosomal dominant cerebellar ataxia type I: A review of the phenotypic and genotypic characteristics

Tri State Mountain Neurology, 105 Woodlawn Dr, Johnson City, TN 27604, USA.
Orphanet Journal of Rare Diseases (Impact Factor: 3.96). 05/2011; 6:33. DOI: 10.1186/1750-1172-6-33
Source: PubMed

ABSTRACT Type I autosomal dominant cerebellar ataxia (ADCA) is a type of spinocerebellar ataxia (SCA) characterized by ataxia with other neurological signs, including oculomotor disturbances, cognitive deficits, pyramidal and extrapyramidal dysfunction, bulbar, spinal and peripheral nervous system involvement. The global prevalence of this disease is not known. The most common type I ADCA is SCA3 followed by SCA2, SCA1, and SCA8, in descending order. Founder effects no doubt contribute to the variable prevalence between populations. Onset is usually in adulthood but cases of presentation in childhood have been reported. Clinical features vary depending on the SCA subtype but by definition include ataxia associated with other neurological manifestations. The clinical spectrum ranges from pure cerebellar signs to constellations including spinal cord and peripheral nerve disease, cognitive impairment, cerebellar or supranuclear ophthalmologic signs, psychiatric problems, and seizures. Cerebellar ataxia can affect virtually any body part causing movement abnormalities. Gait, truncal, and limb ataxia are often the most obvious cerebellar findings though nystagmus, saccadic abnormalities, and dysarthria are usually associated. To date, 21 subtypes have been identified: SCA1-SCA4, SCA8, SCA10, SCA12-SCA14, SCA15/16, SCA17-SCA23, SCA25, SCA27, SCA28 and dentatorubral pallidoluysian atrophy (DRPLA). Type I ADCA can be further divided based on the proposed pathogenetic mechanism into 3 subclasses: subclass 1 includes type I ADCA caused by CAG repeat expansions such as SCA1-SCA3, SCA17, and DRPLA, subclass 2 includes trinucleotide repeat expansions that fall outside of the protein-coding regions of the disease gene including SCA8, SCA10 and SCA12. Subclass 3 contains disorders caused by specific gene deletions, missense mutation, and nonsense mutation and includes SCA13, SCA14, SCA15/16, SCA27 and SCA28. Diagnosis is based on clinical history, physical examination, genetic molecular testing, and exclusion of other diseases. Differential diagnosis is broad and includes secondary ataxias caused by drug or toxic effects, nutritional deficiencies, endocrinopathies, infections and post-infection states, structural abnormalities, paraneoplastic conditions and certain neurodegenerative disorders. Given the autosomal dominant pattern of inheritance, genetic counseling is essential and best performed in specialized genetic clinics. There are currently no known effective treatments to modify disease progression. Care is therefore supportive. Occupational and physical therapy for gait dysfunction and speech therapy for dysarthria is essential. Prognosis is variable depending on the type of ADCA and even among kindreds.

0 Followers
 · 
198 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recognition of the natural history and phenotypic spectrum of a specific disorder is of extreme clinical importance and a difficult task unless a detailed description of multiple individuals is reviewed and available in published literature. Symptoms of SCA27 typically include general cerebellar dysfunction including gait disturbances, tremors, mental retardation and/or developmental delay, dysarthria, and gaze-evoked nystagmus. The age of onset is from childhood to young adulthood, with most individuals having a very slowly progressive adult onset of symptoms beginning with tremors [1-4]. We report here a 4 year old male with a de novo microdeletion of 13q33.1 involving the FGF14 gene who presented with symptoms in the first year of life. This case provides further information on the clinical variability of SCA27 and adds information on the natural history of SCA27 due to the unusual early presentation seen in this case. We review the currently available literature on FGF14 and SCA27 as well as discuss the clinical significance of the FGF14 gene in addition to the importance of utilizing array CGH as a diagnostic tool for SCA27.
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study reports a case of a 75-year-old female Machado-Joseph disease patient exhibiting unstable walking and inaccurate hand holding for 8 months, which progressively worsened. Physical examination on admission showed cerebellar ataxia and a history of hypertension. Cranial MRI demonstrated cerebellar and brain stem atrophy. Gene analysis showed abnormal amplification of the CAG trinucleotide repeat in exon 10 of the ataxin-3 (ATXN3) gene, resulting in 70-81 CAG repeats in the patient, with a significant positive family history.
    Neural Regeneration Research 12/2012; 7(35):2842-7. DOI:10.3969/j.issn.1673-5374.2012.35.013 · 0.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Altered RNA metabolism is a key pathophysiological component causing several neurodegenerative diseases. Genetic mutations causing neurodegeneration occur in coding and non-coding regions of seemingly unrelated genes whose products do not always contribute to the gene expression process. Several pathogenic mechanisms may co-exist within a single neuronal cell, including RNA/protein toxic gain-of-function and/or protein loss-of-function. Genetic mutations that cause neurodegenerative disorders disrupt healthy gene expression at diverse levels, from chromatin remodelling, transcription, splicing, through to axonal transport and repeat-associated non-ATG (RAN) translation. We address neurodegeneration in repeat expansion disorders (Huntington's disease, spinocerebellar ataxias, C9ORF72-related amyotrophic lateral sclerosis) and in diseases caused by deletions or point mutations (spinal muscular atrophy, most subtypes of familial amyotrophic lateral sclerosis). Some neurodegenerative disorders exhibit broad dysregulation of gene expression with the synthesis of hundreds to thousands of abnormal messenger RNA (mRNA) molecules. However, the number and identity of aberrant mRNAs that are translated into proteins - and how these lead to neurodegeneration - remain unknown. The RNA biology research field faces the challenge of identifying pathophysiological events of dysregulated gene expression. In conclusion, we discuss current research limitations and future directions to improve our characterisation of pathological mechanisms that trigger disease onset and progression.
    Neuropathology and Applied Neurobiology 10/2014; 41(2). DOI:10.1111/nan.12187 · 4.97 Impact Factor

Full-text (3 Sources)

Download
56 Downloads
Available from
May 16, 2014